{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T02:20:16Z","timestamp":1760149216116,"version":"build-2065373602"},"reference-count":23,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2023,7,14]],"date-time":"2023-07-14T00:00:00Z","timestamp":1689292800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Ilyang pharmaceutical Co., LTD."}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Background and Objectives: Dyspepsia is a common adverse event associated with the use of nonsteroidal anti-inflammatory drugs (NSAIDs) in patients with lumbar spinal stenosis. Although proton pump and cyclooxygenase-2 inhibitors are potential treatment options, the optimal strategy remains unclear. This study aimed to compare the efficacy and safety of combination therapy with aceclofenac and ilaprazole versus celecoxib monotherapy for the treatment of dyspepsia caused by NSAID use in patients with lumbar spinal stenosis. Materials and\u00a0Methods: This prospective, double-blind, randomized, actively controlled study was conducted at Seoul National University Bundang Hospital in South Korea from July 2020 to September 2021. The participants were randomized into one of two treatment groups: celecoxib monotherapy (control group) and combination therapy with aceclofenac and ilaprazole (test group). The primary efficacy endpoint was the mean change in the Short-Form Leeds Dyspepsia Questionnaire (SF-LDQ) scores from baseline to treatment week 8. The secondary efficacy endpoint was the mean change in Short-Form-12 (SF-12) scores from baseline (week 0) to treatment week 8. Results: The study enrolled 140 patients who were randomly assigned to receive combination therapy with aceclofenac and, ilaprazole or celecoxib. In the per protocol set, the mean change in SF-LDQ scores from week 0 to week 8 was \u22120.51 \u00b1 4.78 and 1.85 \u00b1 6.70 in the combination therapy and celecoxib group, respectively (p = 0.054). SF-12 scores did not differ significantly between the two groups. Adverse events were reported in both groups, but there was no significant difference in incidence. Conclusions: Combination therapy with aceclofenac and ilaprazole can be a treatment option for NSAID-induced dyspepsia in some situations.<\/jats:p>","DOI":"10.3390\/medicina59071307","type":"journal-article","created":{"date-parts":[[2023,7,14]],"date-time":"2023-07-14T08:35:47Z","timestamp":1689323747000},"page":"1307","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Efficacy of Aceclofenac and Ilaprazole Combination Therapy versus Celecoxib Monotherapy for Treating NSAID-Induced Dyspepsia in Lumbar Spinal Stenosis Patients"],"prefix":"10.3390","volume":"59","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6596-9478","authenticated-orcid":false,"given":"Sanghoon","family":"Lee","sequence":"first","affiliation":[{"name":"Department of Orthopedic Surgery, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam-si 13620, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5530-6056","authenticated-orcid":false,"given":"Jung Guel","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Orthopedic Surgery, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam-si 13620, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ho-Joong","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Orthopedic Surgery, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam-si 13620, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2023,7,14]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"968","DOI":"10.31616\/asj.2021.0371","article-title":"An Updated Overview of Low Back Pain Management","volume":"16","author":"Hong","year":"2022","journal-title":"Asian Spine J."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"789","DOI":"10.31616\/asj.2022.0366","article-title":"Lumbar Spinal Stenosis: Review Update 2022","volume":"16","author":"Kwon","year":"2022","journal-title":"Asian Spine J."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"5073","DOI":"10.2174\/1381612821666150915105738","article-title":"Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Induced Dyspepsia","volume":"21","author":"Yap","year":"2015","journal-title":"Curr. Pharm. Des."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1007\/BF02229641","article-title":"The effect of ranitidine on NSAID related dyspeptic symptoms with and without peptic ulcer disease of patients with rheumatoid arthritis and osteoarthritis","volume":"15","author":"Markusse","year":"1996","journal-title":"Clin. Rheumatol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1111\/j.1365-2036.1988.tb00767.x","article-title":"Treatment of endoscopy-negative NSAID-induced upper gastrointestinal symptoms with cimetidine: An international multicentre collaborative study","volume":"2","author":"Bijlsma","year":"1988","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1046\/j.1365-2036.2002.01219.x","article-title":"Dyspepsia tolerability from the patients\u2019 perspective: A comparison of celecoxib with diclofenac","volume":"16","author":"Goldstein","year":"2002","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_7","first-page":"35","article-title":"Upper gastrointestinal tolerability of celecoxib compared with diclofenac in the treatment of osteoarthritis and rheumatoid arthritis","volume":"20","author":"McKenna","year":"2002","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"3651","DOI":"10.2147\/JPR.S326101","article-title":"A Review of Aceclofenac: Analgesic and Anti-Inflammatory Effects on Musculoskeletal Disorders","volume":"14","author":"Iolascon","year":"2021","journal-title":"J. Pain Res."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1097\/MCG.0b013e3181e88515","article-title":"A new PPI, ilaprazole compared with omeprazole in the treatment of duodenal ulcer: A randomized double-blind multicenter trial","volume":"45","author":"Wang","year":"2011","journal-title":"J. Clin. Gastroenterol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1080\/14656566.2016.1232389","article-title":"Ilaprazole for the treatment of gastro-esophageal reflux","volume":"17","author":"Savarino","year":"2016","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1111\/j.1365-2036.2006.03233.x","article-title":"The Short-Form Leeds Dyspepsia Questionnaire validation study","volume":"25","author":"Fraser","year":"2007","journal-title":"Aliment. Pharm. Ther."},{"key":"ref_12","first-page":"151","article-title":"The use of Short Form 12 (SF-12) scores to assess the impact of a pre-habilitation programme","volume":"76","author":"Ledlie","year":"2021","journal-title":"Anaesthesia"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"e0226184","DOI":"10.1371\/journal.pone.0226184","article-title":"A comparative study of the efficacy of NAXOZOL compared to celecoxib in patients with osteoarthritis","volume":"15","author":"Park","year":"2020","journal-title":"PLoS ONE"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1073\/pnas.96.1.272","article-title":"Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: The human pharmacology of a selective inhibitor of COX-2","volume":"96","author":"McAdam","year":"1999","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1056\/NEJM200011233432103","article-title":"Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group","volume":"343","author":"Bombardier","year":"2000","journal-title":"N. Engl. J. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1001\/jama.284.10.1247","article-title":"Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: The CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study","volume":"284","author":"Silverstein","year":"2000","journal-title":"JAMA"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1016\/S0140-6736(00)04451-2","article-title":"NSAIDS and selective COX-2 inhibitors: Competition between gastroprotection and cardioprotection","volume":"357","author":"Boers","year":"2001","journal-title":"Lancet"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1126\/science.1068711","article-title":"Role of prostacyclin in the cardiovascular response to thromboxane A2","volume":"296","author":"Cheng","year":"2002","journal-title":"Science"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1056\/NEJMoa050405","article-title":"Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention","volume":"352","author":"Solomon","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1007\/s00535-009-0072-4","article-title":"Randomized, parallel, double-blind comparison of the ulcer-healing effects of ilaprazole and omeprazole in the treatment of gastric and duodenal ulcers","volume":"44","author":"Ho","year":"2009","journal-title":"J. Gastroenterol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1185\/03007995.2011.639353","article-title":"Ilaprazole for the treatment of duodenal ulcer: A randomized, double-blind and controlled phase III trial","volume":"28","author":"Wang","year":"2012","journal-title":"Curr. Med. Res. Opin."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"5119","DOI":"10.3748\/wjg.v20.i17.5119","article-title":"Efficacy of ilaprazole in the treatment of duodenal ulcers: A meta-analysis","volume":"20","author":"Ji","year":"2014","journal-title":"World J. Gastroenterol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1111\/apt.12860","article-title":"The pharmacokinetics, pharmacodynamics and safety of oral doses of ilaprazole 10, 20 and 40 mg and esomeprazole 40 mg in healthy subjects: A randomised, open-label crossover study","volume":"40","author":"Shin","year":"2014","journal-title":"Aliment. Pharmacol. Ther."}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/59\/7\/1307\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T20:12:14Z","timestamp":1760127134000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/59\/7\/1307"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,14]]},"references-count":23,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2023,7]]}},"alternative-id":["medicina59071307"],"URL":"https:\/\/doi.org\/10.3390\/medicina59071307","relation":{},"ISSN":["1648-9144"],"issn-type":[{"type":"electronic","value":"1648-9144"}],"subject":[],"published":{"date-parts":[[2023,7,14]]}}}